Currently Empty: $0.00
Vial - lyophilised powderSubcutaneous (SQ)5 mg
A stabilised GHRH analogue approved by the FDA for the reduction of excess visceral abdominal fat, and one of the best-evidenced compounds in the portfolio.
Delivery and return
Delivery and return
| Standard Delivery (Signed for) | Delivered within 3-5 working days |
| Express Delivery (Standard Parcels) | Delivered within 1-2 working days |
| Extra-Large Parcels (Signed for) | Delivered within 3-5 working days |
| Furniture | Delivery usually takes place within 2 weeks. |
Shipping Information
Shipping Information
Free Shipping
Decor Outdoor offers free regular shipping on all orders shipped to residential or commercial addresses within the contiguous United States. Orders are delivered Monday through Friday (excluding holidays).Drop Shipping
We are an online-only luxury furniture and lighting boutique, and do not have a warehouse. Consequently, all orders are drop shipped directly from our manufacturers to your door. If your order includes items from more than one manufacturer, you will receive multiple deliveries. Because we are dependent on the on-hand inventory of our manufacturing partners, some items listed on our site may not actually be available right away. Please call us at 888.784.4644 or via our contact form with any stocking questions and we'll get in touch with the appropriate manufacturer for answers, before you place your order.Ground Shipping
Small parcel items ship regular ground via delivery services such as FedEx, UPS or DHL. Orders typically take 2-3 business days to process and in-stock items will usually be delivered 3-5 days from the date that they ship (depending on origin and destination). If there is a delay, you will be notified by email. No signature is required for standard ground shipping, so you may want to make arrangements to have packages brought inside soon after delivery, if you are unable to receive it in person.Composition and care
Composition and care
We speak a lot about the importance of gut health—not only for beauty—but also in terms of our overall health, wellbeing and immunity. But before we can fully understand why the gut is so integral to our health, it’s first essential to learn more about the physiology of the gut itself—and how it works.
Research Handling Note
Allow sealed vials to equilibrate to ambient laboratory temperature before opening. This helps minimise the risk of condensation forming within the vial. Keep unopened vials stored at 2-8 C, protected from direct light and moisture. All handling, storage after opening, and laboratory procedures should be carried out according to the receiving laboratory’s established protocols and applicable requirements.
Tesamorelin is a synthetic analogue of human growth hormone releasing hormone (1-44), stabilised by a trans-3-hexenoyl modification at the N-terminus. It is approved by the FDA as Egrifta for the reduction of excess visceral adipose tissue in adults with HIV-associated lipodystrophy, supported by two Phase III randomised placebo-controlled trials that demonstrated a consistent and specific reduction in visceral rather than subcutaneous fat. Later investigator-led work has examined its effect on hepatic fat in non-alcoholic fatty liver disease, with positive findings, and separate work has explored cognitive endpoints. It is therefore among the strongest evidence positions in this range – with the important qualification that the evidence is specific to a defined clinical population, and that use outside that population is off-label.
Active Compound: Tesamorelin (trans-3-hexenoyl-GHRH 1-44 analogue)
Permitted Claim GuidelinesA GHRH analogue approved in the United States for a specific licensed indication. Supplied on prescription for practitioner-directed use.
Mechanism of Action
Binds the GHRH receptor on anterior pituitary somatotrophs, stimulating pulsatile endogenous growth hormone release and consequent hepatic IGF-1 production. Growth hormone promotes lipolysis in visceral adipose tissue preferentially over subcutaneous depots, which accounts for the specificity of the observed effect.
Evidence Grade: A - FDA-approved with Phase III evidence in the licensed population
Clinical Evidence BaseTwo Phase III randomised placebo-controlled trials in HIV-associated lipodystrophy demonstrated significant reduction in visceral adipose tissue, supporting FDA approval. Subsequent randomised trials reported reduction in hepatic fat and slowed fibrosis progression in NAFLD. Evidence in the general population without lipodystrophy is limited.
Literature & ReferencesFalutz J et al. N Engl J Med, 2007 - tesamorelin and visceral adipose tissue in HIV-associated lipodystrophy. | Falutz J et al. J Acquir Immune Defic Syndr, 2010 - Phase III long-term efficacy and safety. | Stanley TL et al. Lancet HIV, 2019 - tesamorelin for hepatic fat in HIV-associated NAFLD. | US FDA prescribing information, Egrifta (tesamorelin for injection).
Safety & Precautions
Adverse effects reflect growth hormone elevation: arthralgia, peripheral oedema, myalgia, paraesthesia and injection-site reactions. Impaired glucose tolerance and increased blood glucose occur and require monitoring, particularly in patients with diabetes or pre-diabetes. Contraindicated in active malignancy given IGF-1 elevation, in pituitary disease and in pregnancy. Baseline and periodic IGF-1 and glucose monitoring should be standard. Benefit is not maintained after discontinuation.
ContraindicationsActive malignancy; disruption of the hypothalamic-pituitary axis or pituitary tumour; pregnancy; known hypersensitivity to tesamorelin or mannitol.
Storage & HandlingStore lyophilised vial at 2-8 C, protected from light.
Regulatory Status
Approved in the United States (Egrifta) for a specific indication; not authorised in the UK or EU. Prohibited in sport under the WADA Prohibited List (S2). The product supplied here is not the licensed presentation; use is off-label and prescription-medicine advertising restrictions apply.
